S5 Ep44: Monk Talks Tisotumab Vedotin and Exciting ESMO Data in Cervical Cancer

OncLive® On Air - A podcast by OncLive® On Air

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

Dr. Monk discusses the significance of the FDA approval of tisotumab vedotin and notable research that was presented at the 2021 ESMO Congress in cervical cancer.

Visit the podcast's native language site